<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04507204</url>
  </required_header>
  <id_info>
    <org_study_id>ADA4003</org_study_id>
    <nct_id>NCT04507204</nct_id>
  </id_info>
  <brief_title>Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <acronym>RE-DAX</acronym>
  <official_title>Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at&#xD;
      month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with&#xD;
      the active comparator group (Concerta) over time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase IV study is a prospective, open-label, randomized, pragmatic study to investigate&#xD;
      the treatment effectiveness of Adhansia XR at Month-2 after initiation, and the effectiveness&#xD;
      of Adhansia XR overall and when compared with the active comparator group (OROS MPH or&#xD;
      Concerta) over time. Additional outcome assessments for both treatment arms include&#xD;
      Health-Related Quality of Life (HRQoL) during the 6-month follow-up period. The burden of&#xD;
      illness (BOI) will be investigated by collecting additional measures such as healthcare&#xD;
      resource utilization (HCRU), broader treatment patterns, and comorbidities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ADHD-Rating Scale 5 Total Score from Baseline to Month 2</measure>
    <time_frame>Baseline to Month-2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Time Sensitive ADHD Symptom Scale (TASS) Between Treatment Groups</measure>
    <time_frame>Month-2</time_frame>
    <description>TASS to be completed at the end of waking hours (14 - 16 hours post-dosing) at Month-2 after baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Global Impression-Severity (CGI-S)</measure>
    <time_frame>Baseline, Month-2, Month-4, and Month-6</time_frame>
    <description>The CGI-S rates symptoms from 1 (not ill) to 7 (extremely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Global Impression-Improvement (CGI-I)</measure>
    <time_frame>Month-2, Month-4, and Month-6</time_frame>
    <description>The CGI-I measures global improvement prior to and after initiating the study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Treatment Satisfaction</measure>
    <time_frame>Month-1, Month-2, and Month-6</time_frame>
    <description>The Treatment Satisfaction Questionnaire for Medications (TSQM) measures a patient's level of satisfaction or dissatisfaction with the study medication. It assesses perceptions of effectiveness, side effects and convenience of the medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU)</measure>
    <time_frame>Months -1, -2, -3, -4, -5, and -6</time_frame>
    <description>A comparison of the frequency of health care encounters between the 2 treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult ADHD Quality of Life Scale - Revised (AAQoL-R)</measure>
    <time_frame>Baseline, Months -1, -2, -3, -4, -5 and -6</time_frame>
    <description>Used to assess health-related quality of life for adult patients. The AAQoL yields a total score based on 29 items. The raw scores are transformed to a 0 to 100 scale with higher scores indicating a better QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment (WPAI) Questionnaire</measure>
    <time_frame>Baseline, Months -2, -3, -4, -5, and -6</time_frame>
    <description>The WPAI questionnaire measures work time missed and work and activity impairment because of a specified health problem during the past 7 days for adult patients. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale</measure>
    <time_frame>Baseline, Months -2, -3, -4, -5, and -6</time_frame>
    <description>Used to assess health-related quality of life of adolescent patients. The DPREMB-R is a parent/caregiver completed 11-item questionnaire; it measures the difficulty level of 8 common evening behaviors (such as, sit through dinner) and 3 common morning behaviors (such as, get out of bed). Each item is scored on a 4-point Likert scale ranging from 0 (no difficulty) to 3 (a lot of difficulty). Total score ranges from 0 to 33, where higher scores indicate greater difficulty in evening and morning behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline and Months -2, -4, and -6</time_frame>
    <description>The PSQI is an instrument used to measure the quality and patterns of sleep; It differentiates &quot;poor&quot; from &quot;good&quot; sleep. It is filled out by the caregiver or the patient and the global sum score ranges from 0 to 21, with higher scores indicating worse sleep quality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Attention-Deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Adhansia XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adhansia XR capsules taken orally once daily with or without food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concerta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adhansia XR</intervention_name>
    <description>Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)</description>
    <arm_group_label>Adhansia XR</arm_group_label>
    <other_name>Methylphenidate hydrochloride (HCl) extended release</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concerta</intervention_name>
    <description>An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)</description>
    <arm_group_label>Concerta</arm_group_label>
    <other_name>Methylphenidate hydrochloride (HCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a physician-confirmed diagnosis of ADHD per Diagnostic and Statistical&#xD;
             Manual of Mental Disorders (DSM-5) criteria and the health care practitioner (HCP) has&#xD;
             made the decision to prescribe an extended-release methylphenidate (ER MPH) product to&#xD;
             the patient for potential improvement of symptoms throughout and later in the day,&#xD;
             independent of this study.&#xD;
&#xD;
          -  Patient must be 12 years of age or older.&#xD;
&#xD;
          -  Patient must be eligible to receive Adhansia XR or osmotic- release oral delivery&#xD;
             system methylphenidate ([OROS MPH] or Concerta) according to the US product labels; a&#xD;
             patient must be eligible and willing to receive either drug, as randomization will&#xD;
             assign them to a specific treatment group. Patient may be treatment-experienced or&#xD;
             na√Øve to pharmacological therapy for ADHD, so long as all inclusion and no exclusion&#xD;
             criteria are met.&#xD;
&#xD;
          -  Patient must be willing to take only the assigned study medication per HCP&#xD;
             instructions based on FDA label guidance for treatment of their ADHD for the first 2&#xD;
             months of the study (i.e. full titration period). Patients should not be on any other&#xD;
             medication, or starting any new non-medication treatment, proven to have effect on&#xD;
             ADHD in the first two months of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent participation in an investigational study in which patient assessment&#xD;
             and/or treatment may be dictated by a protocol.&#xD;
&#xD;
          -  Patients with a true allergy to methylphenidate (MPH), amphetamine (AMP), or&#xD;
             sympathomimetic amines, history of serious adverse reactions to MPH or AMP or be known&#xD;
             to be non-responsive to MPH or AMP treatment.&#xD;
&#xD;
          -  Patient is currently stable on their ADHD treatment regimen.&#xD;
&#xD;
          -  Female patients of child bearing potential who are pregnant, planning on becoming&#xD;
             pregnant or breastfeeding.&#xD;
&#xD;
          -  Patient with any known conditions that are contraindicated for either Adhansia XR or&#xD;
             OROS MPH (or Concerta) use, as documented in the US Full Prescribing Information,&#xD;
             including patients with any known serious structural cardiac abnormalities,&#xD;
             cardiomyopathy, serious heart arrhythmias, or coronary artery disease.&#xD;
&#xD;
          -  Patients with a known sensitivity to the food dye tartrazine (Federal Food, Drug, and&#xD;
             Cosmetic Yellow No. 5).&#xD;
&#xD;
          -  Suicidal Ideation&#xD;
&#xD;
               -  The Columbia-Suicide Severity Rating Scale (C-SSRS) will be administered at&#xD;
                  screening and at Month-2, Month-4, and Month-6, but also depends on the judgment&#xD;
                  of the HCP.&#xD;
&#xD;
          -  Inability or unwillingness of the patient (or parent/guardian if patient is a minor)&#xD;
             to complete the study-required electronic questionnaires and provide required&#xD;
             information through electronic means.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jaromir Mikl, PhD MSHP</last_name>
    <phone>800-745-7445</phone>
    <phone_ext>7277</phone_ext>
    <email>Jaromir.Mikl@pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harmonex, Inc.</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Research LLC</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CT Clinical Research</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Clinical Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reliable Clinical Research, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Research. Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellness Research Center Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group Pediatrics at Orange City</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Epilepsy &amp; Neurology Specialists</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Integrative Research Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute</name>
      <address>
        <city>Elgin</city>
        <state>Illinois</state>
        <zip>60123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR-Baber Research Inc.</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BTC of New Bedford, LLC</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Medicine Group</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochester Center for Behavioral Medicine</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric Care and Research Center</name>
      <address>
        <city>O'Fallon</city>
        <state>Missouri</state>
        <zip>63368</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates - Midwest Research Group</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Southern Nevada, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bioscience Research, LLC</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid-Ohio Behavioral Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SFM Clinical Trials</name>
      <address>
        <city>Scotland</city>
        <state>Pennsylvania</state>
        <zip>17254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow Research</name>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>29812</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research, LLC</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Road Runner Research, Ltd.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dixie Pediatrics</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Petersburg</city>
        <state>Virginia</state>
        <zip>23805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastside Therapeutic Resource Inc dba Core Clinical Research</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System - Rockwood Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Methylphenidate</keyword>
  <keyword>Adhansia XR</keyword>
  <keyword>MPH</keyword>
  <keyword>OROS</keyword>
  <keyword>Phase IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

